Consortium
The INNOTISSUE Erasmus Mundus Joint Master Programme is delivered through a strategically designed consortium of three complementary European institutions, forming a fully integrated education–research–innovation ecosystem.
Rather than a simple partnership, the consortium operates as a coherent “innovation value chain”, where each institution contributes to a specific phase of the biomaterials and tissue engineering lifecycle.
🌍 A Unique European Innovation Corridor
INNOTISSUE establishes a structured academic and innovation pathway across Europe:
- Türkiye (YTU) → Clinical relevance & foundational biomaterials training
- Romania (UNSTPB) → Advanced materials engineering & industrial scale-up
- Spain (UIC) → Clinical translation & biomedical application
👉 This geographical and functional integration enables students to experience the full journey:
from material design → fabrication → validation → clinical application
Yıldız Technical University (YTU) – Türkiye
YTU serves as the coordinating institution and the academic backbone of the programme.
Key contributions:
- Delivery of the first-year integrated curriculum (core scientific foundation)
- Expertise in biomaterials, tissue engineering, polymer science, and biofabrication
- Strong connection to high-volume clinical environments and application needs
- Advanced research infrastructure:
- biomaterials laboratories
- cell culture facilities
- characterization platforms
YTU also leads:
- Programme coordination and governance
- Digital infrastructure (application system, student tracking, QA systems)
- Student lifecycle management
National University of Science and Technology POLITEHNICA Bucharest (UNSTPB) – Romania
UNSTPB represents the engineering and industrial dimension of the programme.
Key strengths:
- Advanced expertise in:
- materials processing
- nanotechnology
- surface engineering
- biofabrication technologies
- State-of-the-art facilities for:
- SEM / AFM characterization
- mechanical and structural analysis
- Strong integration with industrial partners and manufacturing ecosystems
👉 Role in INNOTISSUE:
- Transforming laboratory concepts into validated and scalable solutions
- Supporting regulatory-aligned material testing and performance analysis
Universitat Internacional de Catalunya (UIC) – Spain
UIC provides the clinical and translational dimension of the programme.
Core capabilities:
- Expertise in:
- bioengineering for human health
- cell-based therapies
- medical device development
- clinical trial frameworks
- Direct links with:
- hospitals
- clinical research centers
- biomedical startups
👉 Role in INNOTISSUE:
- Bridging innovation with real clinical needs
- Enabling clinical validation and application-oriented research
- Supporting entrepreneurship and healthcare innovation pathways
Complementarity and Functional Integration
What makes INNOTISSUE unique is not only the strength of each partner—but how they are integrated.
🔗 A Complete Innovation Value Chain
The consortium enables a seamless transition across:
- Scientific Design (YTU)
- Engineering & Validation (UNSTPB)
- Clinical Translation (UIC)
👉 This structure directly addresses the “design-to-clinic” gap in biomaterials.
🌐 Beyond the Core: A Multi-Stakeholder Ecosystem
INNOTISSUE is further strengthened by a network of:
- 20+ associated partners
- Industrial stakeholders (biotech, medical devices)
- Academic and clinical collaborators
These partners contribute to:
- internships
- thesis supervision
- certified training modules
- real-world problem solving
🚀 Proven Collaboration and Strategic Synergy
The consortium builds on existing collaborations and EU-funded initiatives, demonstrating:
- Established academic cooperation
- Shared research outputs
- Experience in international project management
This ensures that INNOTISSUE is not only a new programme—but a mature, reliable, and scalable partnership.
🎯 More Than a Consortium
INNOTISSUE is not just a group of institutions.
It is a jointly governed European platform designed to:
- integrate education, research, and innovation
- train next-generation biomedical leaders
- deliver long-term impact in healthcare systems
